GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intelgenx Technologies Corp (OTCPK:IGXT) » Definitions » Price-to-Owner-Earnings

Intelgenx Technologies (Intelgenx Technologies) Price-to-Owner-Earnings : (As of May. 28, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Intelgenx Technologies Price-to-Owner-Earnings?

As of today (2024-05-28), Intelgenx Technologies's share price is $0.167. Intelgenx Technologies does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Intelgenx Technologies's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Intelgenx Technologies was 293.33. The lowest was 26.36. And the median was 72.00.


IGXT's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.11
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-28), Intelgenx Technologies's share price is $0.167. Intelgenx Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.06. Therefore, Intelgenx Technologies's PE Ratio for today is At Loss.

As of today (2024-05-28), Intelgenx Technologies's share price is $0.167. Intelgenx Technologies's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.06. Therefore, Intelgenx Technologies's PE Ratio without NRI for today is At Loss.

During the past 13 years, Intelgenx Technologies's highest PE Ratio without NRI was 98.33. The lowest was 0.00. And the median was 35.33.


Intelgenx Technologies Price-to-Owner-Earnings Historical Data

The historical data trend for Intelgenx Technologies's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelgenx Technologies Price-to-Owner-Earnings Chart

Intelgenx Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Intelgenx Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Intelgenx Technologies's Price-to-Owner-Earnings

For the Biotechnology subindustry, Intelgenx Technologies's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intelgenx Technologies's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intelgenx Technologies's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Intelgenx Technologies's Price-to-Owner-Earnings falls into.



Intelgenx Technologies Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Intelgenx Technologies's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.167/-0.04
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intelgenx Technologies  (OTCPK:IGXT) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Intelgenx Technologies Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Intelgenx Technologies's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Intelgenx Technologies (Intelgenx Technologies) Business Description

Traded in Other Exchanges
Address
6420 Abrams, Ville Saint Laurent, QC, CAN, H4S 1Y2
Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. Intelegenx focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and United States.
Executives
Atai Life Sciences Ag 10 percent owner KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Atai Life Sciences N.v. 10 percent owner 524 BROADWAY, NEW YORK NY 10013
Karen Kalayajian officer: VP, Finance&Admin - Subsidiary 4896 RUE EDOUARD-BRUNETTE, LAVAL A8 H7T 0J4
Dwight Gorham officer: CEO 15B BARKLEY ST, ARNPRIOR A6 K7S 3G8
David Kideckel officer: SVP, Corp. Dev&SA - Subsidiary 23 PEVERIL HILL SOUTH, TORONTO, ON A6 M6C 3A7
Horst G Zerbe 10 percent owner, officer: Chief Executive Officer 714 MAIN ROAD, HUDSON A8 JOP1H0
Andre Godin officer: CFO 440 DES CARMANTINES, LAVAL A8 H7X 0B6
Tommy Kenny officer: VP IP,Lgl Affairs - Subsidiary 88 CH. DES SAULES, ST-ADOLPHE D' HOWARD A8 J0T 2B0
Dana Matzen officer: VP Business+Corp. Development 4771 RUE SHERBROOKE O., WESTMOUNT A8 H3Z1G5
Ingrid Zerbe 10 percent owner, officer: Corporate Secretary 714 MAIN ROAD, HUDSON A8 J0P1H0
Rodolphe Obeid officer: Vice President, Operations 4779 RUE VILLERET, PIERREFOND A8 H9K1P6
Bernard Boudreau director 2 TURNMILL DR., HALIFAX A5 B3M4H2
John Edward Durham officer: Vice President Manufacturing 102 MAYFAIR, HUDSON A8 J0P1H0
Mark Nawacki director 118 ARLINGTON AVENUE, WESTMOUNT A8 H3Y2W4
Robert J. Bechard officer: VP Corporate Development 141 EASTON AVENUE, MONTREAL WEST A8 H4X 1L4